Late-onset Alzheimer’s disease (LOAD) is the most common form of dementia worldwide. To date, animal models of Alzheimer’s have focused on rare familial mutations, due to a lack of frank neuropathology from models based on common disease genes. Recent multi-cohort studies of postmortem human brain transcriptomes have identified a set of 30 gene co-expression modules associated with LOAD, providing a molecular catalog of relevant endophenotypes. This resource enables precise gene-based alignment between new animal models and human molecular signatures of disease. Here, we describe a new resource to efficiently screen mouse models for LOAD relevance. A new NanoString nCounter® Mouse AD Panel was designed to correlate key human disease processes and pathways with mRNA expression from mouse brains. Analysis of two mouse models based on LOAD genetics, carrying APOE4 and TREM2.R47H alleles, demonstrated overlaps with distinct human AD modules that, in turn, are functionally enriched in key disease-associated pathways. Comprehensive comparison with full transcriptome data from same-sample RNA-seq shows strong correlation between gene expression changes independent of experimental platform. Taken together, we show that the nCounter Mouse AD Panel offers a rapid, cost-effective and highly reproducible approach to assess disease relevance of potential LOAD mouse models.
Learning Objectives:
1. Reproducibly screen potential LOAD mouse models to assess disease relevance
2. Understand design of a new resource, the Mouse AD Panel, to translate human disease processes and pathways to mouse models
Animal Models
Neuroscience
Animal Research
Brain
Cell Biology
Disease
Molecular Biology
Molecular Neuroscience
Brain Diseases
Human Genetics
Biomarkers
Cell Culture
Molecular Genetics
Immunology
Research
Europe50%
North America43%
Website Visitors100%
Scientist29%
Medical Laboratory Technician21%
Post Doc14%
Student7%
Executive7%
Facility/Department Manager7%
Biologist7%
Marketing/Sales7%
Academic Institution43%
Biotech Company14%
Hospital14%
Medical School7%
Pharmaceutical Company7%
Life Science Company7%
Other7%